Athelas’ activities focus on the development of bacterical anti-virulence drugs, the identification of bacterial genes involved in the virulence mechanisms and their use as new drug targets. The company developed a proprietary technology uniquely capable to screen and identify compounds and bacterial gene targets affecting the virulence of human pathogens, which position Athelas as an unchallenged leader in the field of new anti-bacterial drug discovery.